ERBB2 and triple-negative breast carcinoma: Indeed, while the mere presence of residual disease after neoadjuvant chemotherapy has been endorsed as a fit criterion for selecting high-risk triple-negative breast cancer patients for clinical trials testing escalated post-neoadjuvant strategies, this might not be the more reliable strategy for selecting high-risk patients with HR-positive/HER2- breast cancer, given the known sub-optimality of pCR as a surrogate prognostic biomarker in this breast cancer subtype27.